Biotechnology

Aurinia Pharma

Aurinia Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 77.71 M (forecast USD 76.98 M), actual EPS USD 0.25 (forecast USD 0.195)

Aurinia Pharmaceuticals Agrees to $6.955 Per Share Cash Acquisition of Kezar Life Sciences

Aurinia Pharma released FY2025 annual earnings on February 26 Pre-Market (EST), actual revenue USD 283.06 M (forecast USD 280.63 M), actual EPS USD 2.07 (forecast USD 0.7816)

Aurinia Pharma released FY2025 Q4 earnings on February 26 Pre-Market EST, actual revenue USD 77.11 M (forecast USD 74.7 M), actual EPS USD 1.5249 (forecast USD 0.2166)

Aurinia Pharma to Release FY2025 Q4 Earnings on February 26 Pre-Market EST, Forecast Revenue USD 74.7 M, EPS USD 0.2166

Analyst Miehm Gives Aurinia Pharmaceuticals a Modest Buy Rating

Aurinia Pharma released FY2025 Q3 earnings on November 4 Pre-Market (EST), actual revenue USD 73.47 M (forecast USD 67.7 M), actual EPS USD 0.23 (forecast USD 0.16)

Aurinia Pharma released FY2025 9 Months Earnings on November 4 Pre-Market (EST), with actual revenue of USD 205.94 M and EPS of USD 0.5495

Aurinia Pharmaceuticals Reports Q3 Financial Results

Aurinia Pharmaceuticals Expects EPS of 16 Cents

Aurinia Pharmaceuticals Responds to FDA's Post About Drug Withdrawal

Aurinia Pharmaceuticals Reaches 52-Week High

Aurinia Pharma released FY2025 Q2 earnings on July 31 Pre-Market EST, actual revenue USD 0 (forecast USD 63.8 M), actual EPS USD 0 (forecast USD 0.1466)

Aurinia Pharma released FY2025 Semi-Annual earnings on July 31 Pre-Market EST, actual revenue USD 132.47 M, actual EPS USD 0.32

Aurinia Pharmaceuticals Reports Second Quarter Financials

Aurinia Pharma to release FY2025 Q2 earnings report on July 31 Pre-Market EST, forecast revenue USD 64.27 M, EPS USD 0.144

Aurinia's ARITINERCEPT Phase 1 Study Shows Positive Results

Aurinia Pharma released FY2025 Q1 earnings on May 12 Pre-Market EST, actual revenue USD 62.47 M (forecast USD 61.06 M), actual EPS USD 0.16 (forecast USD 0.1)

Aurinia Pharmaceuticals Reports 24% Q1 2025 Revenue Growth

Aurinia Pharmaceuticals to Release Q1 2025 Earnings on May 12, 2025

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

AUPH

SBIO

Aurinia Pharmaceuticals has completed the acquisition of approximately 80.24% of Kezar Life Sciences' outstanding common stock for $6.955 per share, following a merger agreement signed on March 30, 2026. The remaining shares were converted in a follow-on merger, making Kezar a wholly owned subsidiary. The latest analyst rating for Aurinia (AUPH) is a Hold with a $15.00 price target, while Spark's AI Analyst rates it as Outperform due to strong financial performance and growth outlook, despite some risks.

Tip Ranks

Kezar Life Sciences

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares US Pharma

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences

Aurinia Pharmaceuticals shares are trading lower. The company reported Q1 financial results and affirmed FY26 sales guidance below estimates.

benzinga_article

Earnings Watch

Aurinia Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 77.71 M

CRBG

AKRO

ULYX

Halper Sadeh LLC is investigating Kezar Life Sciences, Equitable Holdings, and Urgent.ly for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. They are encouraging shareholders to discuss their rights and options regarding the proposed transactions, which include KZR's sale to Aurinia Pharmaceuticals, EQH's merger with Corebridge Financial, and ULYX's sale to Agero. Halper Sadeh LLC offers legal assistance on a contingent fee basis.

prnewswire

Urgently

Equitable

Corebridge Financial

Akero Therapeutics

Urgent.ly Inc.

16:13 ETAre KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders?

INDA

SMIN

Indian equity indices, Sensex and Nifty50, are set to open higher following a US-Iran ceasefire agreement. Key stocks to watch include Infosys, which has partnered with Harness for AI-led software delivery, and Aurobindo Pharma, which received USFDA approval for new drug formulations. GAIL signed a long-term LNG charter with Alpha Gas, while Aditya Birla Real Estate reported ₹1,600 crore in bookings for a luxury project. Clean Max Enviro Energy launched a renewable energy project, and Biocon announced the US launch of new products. SRF faces a tax demand issue, and Ashiana Housing reported significant growth in bookings.

Aurinia Pharma(AUPH.US)

Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences

Aurinia Pharmaceuticals shares are trading lower. The company reported Q1 financial results and affirmed FY26 sales guidance below estimates.

Aurinia Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 77.71 M

16:13 ETAre KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders?

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL